118 related articles for article (PubMed ID: 36029371)
21. Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (< 3 cm) After Transarterial Chemoembolization.
Lee BC; Jeong YY; Heo SH; Kim HO; Park C; Shin SS; Cho SB; Koh YS
Acad Radiol; 2022 Sep; 29(9):e178-e188. PubMed ID: 35151549
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization.
Baek MY; Yoo JJ; Jeong SW; Jang JY; Kim YK; Jeong SO; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim YJ; Park SY
Korean J Intern Med; 2019 Nov; 34(6):1223-1232. PubMed ID: 30360019
[TBL] [Abstract][Full Text] [Related]
23. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
[TBL] [Abstract][Full Text] [Related]
24. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma.
Kim BK; Kim SU; Kim KA; Chung YE; Kim MJ; Park MS; Park JY; Kim DY; Ahn SH; Kim MD; Park SI; Won JY; Lee DY; Han KH
J Hepatol; 2015 Jun; 62(6):1304-10. PubMed ID: 25637785
[TBL] [Abstract][Full Text] [Related]
25. Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma.
Choi JW; Chung JW; Lee DH; Kim HC; Hur S; Lee M; Jae HJ
Eur Radiol; 2018 May; 28(5):2184-2193. PubMed ID: 29218611
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
[TBL] [Abstract][Full Text] [Related]
27. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis.
Risaliti M; Bartolini I; Campani C; Arena U; Xodo C; Adotti V; Rosi M; Taddei A; Muiesan P; Amedei A; Batignani G; Marra F
World J Gastroenterol; 2022 Aug; 28(29):3981-3993. PubMed ID: 36157535
[TBL] [Abstract][Full Text] [Related]
29. Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization.
Tian M; Zhang X; Huang G; Fan W; Li J; Zhang Y
Abdom Radiol (NY); 2019 Oct; 44(10):3304-3311. PubMed ID: 31250181
[TBL] [Abstract][Full Text] [Related]
30. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
31. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
32. Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus.
Choi JW; Kim HC; Lee JH; Yu SJ; Kim YJ; Yoon JH; Jae HJ; Hur S; Lee M; Chung JW
Eur Radiol; 2017 Apr; 27(4):1448-1458. PubMed ID: 27516356
[TBL] [Abstract][Full Text] [Related]
33. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
[TBL] [Abstract][Full Text] [Related]
34. Lens culinaris agglutinin-reactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization.
Song BC; Suh DJ; Yang SH; Lee HC; Chung YH; Sung KB; Lee YS
J Clin Gastroenterol; 2002; 35(5):398-402. PubMed ID: 12394228
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
[TBL] [Abstract][Full Text] [Related]
36. Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study.
Toro A; Ardiri A; Mannino M; Arcerito MC; Mannino G; Palermo F; Bertino G; Di Carlo I
BMC Surg; 2014 Jul; 14():40. PubMed ID: 24993566
[TBL] [Abstract][Full Text] [Related]
37. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
[TBL] [Abstract][Full Text] [Related]
38. Radiofrequency Ablation (RFA) Combined with Transcatheter Arterial Chemoembolization (TACE) for Patients with Medium-to-Large Hepatocellular Carcinoma: A Retrospective Analysis of Long-Term Outcome.
Liu W; Xu H; Ying X; Zhang D; Lai L; Wang L; Tu J; Ji J
Med Sci Monit; 2020 Jul; 26():e923263. PubMed ID: 32667906
[TBL] [Abstract][Full Text] [Related]
39. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization.
Jin YJ; Chung YH; Kim JA; Park W; Lee D; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Kim PN; Sung KB
Dig Dis Sci; 2013 Jun; 58(6):1758-65. PubMed ID: 23361574
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization.
Gabr A; Abouchaleh N; Ali R; Vouche M; Atassi R; Memon K; Asadi AA; Baker T; Caicedo JC; Desai K; Fryer J; Hickey R; Abeccassis M; Habib A; Hohlastos E; Ganger D; Kulik L; Lewandowski RJ; Riaz A; Salem R
Eur J Radiol; 2017 Aug; 93():100-106. PubMed ID: 28668402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
